Contulakin-G is the synthetic form of a natural peptide extracted from the venom of the Conus Geographus sea snail that used in animal models as a broad-spectrum non-opioid analgesic. Contulakin-G was previously shown to be an agonist for all three subtypes of neurotensin receptors, NTS1, NTS2, and NTS3 with submicromolar potency. Contulakin-G exhibited potent analgesic activity in three pain models in rats following intrathecal delivery, namely in tail-flick (acute pain), formalin test, and CFA-induced allodynia inflammatory pain. Contulakin-G (coded as CGX-1160) was granted an orphan drug designation by the US Food and Drug Administration (FDA) and reached a clinical development stage for the treatment of chronic intractable pain following intrathecal administration in patients with spinal cord injury